Blood pentobarbital concentrations during thiopental therapy

W. A. Watson, P. J. Godley, J. C. Garriott, J. Chris Bradberry, J. D. Puckett

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The desulfuration of thiopental to pentobarbital has previously been shown to be a relatively minor pathway of thiopental metabolism. In two cases, we observed significant conversion, resulting in blood pentobarbital concentrations up to 50 percent of total blood barbiturate (thiopental and pentobarbital) concentrations. Both patients received continuous infusions of thiopental and had present a condition (hypothermia) or drug (cimetidine) known to inhibit hepatic microsomal enzyme activity. It is suggested that inhibition of hepatic microsomal enzyme activity may prevent thiopental's metabolism to its major metabolite, a carboxylic acid analogue, and increase the amount of thiopental desulfurated to pentobarbital. Inhibition of hepatic microsomal metabolism also decreases the metabolism of pentobarbital. Until further elucidation of the causes of altered thiopental metabolism is available to identify patients more likely to have elevated concentrations of pentobarbital, monitoring of blood drug concentrations in patients receiving thiopental should include determination of both thiopental and pentobarbital concentrations.

Original languageEnglish
Pages (from-to)283-287
Number of pages5
JournalDrug Intelligence and Clinical Pharmacy
Volume20
Issue number4
StatePublished - 1986
Externally publishedYes

Fingerprint

Thiopental
Pentobarbital
Therapeutics
Liver
Drug Monitoring
Cimetidine
Enzymes
Carboxylic Acids
Hypothermia

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Watson, W. A., Godley, P. J., Garriott, J. C., Bradberry, J. C., & Puckett, J. D. (1986). Blood pentobarbital concentrations during thiopental therapy. Drug Intelligence and Clinical Pharmacy, 20(4), 283-287.

Blood pentobarbital concentrations during thiopental therapy. / Watson, W. A.; Godley, P. J.; Garriott, J. C.; Bradberry, J. Chris; Puckett, J. D.

In: Drug Intelligence and Clinical Pharmacy, Vol. 20, No. 4, 1986, p. 283-287.

Research output: Contribution to journalArticle

Watson, WA, Godley, PJ, Garriott, JC, Bradberry, JC & Puckett, JD 1986, 'Blood pentobarbital concentrations during thiopental therapy', Drug Intelligence and Clinical Pharmacy, vol. 20, no. 4, pp. 283-287.
Watson, W. A. ; Godley, P. J. ; Garriott, J. C. ; Bradberry, J. Chris ; Puckett, J. D. / Blood pentobarbital concentrations during thiopental therapy. In: Drug Intelligence and Clinical Pharmacy. 1986 ; Vol. 20, No. 4. pp. 283-287.
@article{afcfa2cac57e4d9cb67dbd93b6140aa7,
title = "Blood pentobarbital concentrations during thiopental therapy",
abstract = "The desulfuration of thiopental to pentobarbital has previously been shown to be a relatively minor pathway of thiopental metabolism. In two cases, we observed significant conversion, resulting in blood pentobarbital concentrations up to 50 percent of total blood barbiturate (thiopental and pentobarbital) concentrations. Both patients received continuous infusions of thiopental and had present a condition (hypothermia) or drug (cimetidine) known to inhibit hepatic microsomal enzyme activity. It is suggested that inhibition of hepatic microsomal enzyme activity may prevent thiopental's metabolism to its major metabolite, a carboxylic acid analogue, and increase the amount of thiopental desulfurated to pentobarbital. Inhibition of hepatic microsomal metabolism also decreases the metabolism of pentobarbital. Until further elucidation of the causes of altered thiopental metabolism is available to identify patients more likely to have elevated concentrations of pentobarbital, monitoring of blood drug concentrations in patients receiving thiopental should include determination of both thiopental and pentobarbital concentrations.",
author = "Watson, {W. A.} and Godley, {P. J.} and Garriott, {J. C.} and Bradberry, {J. Chris} and Puckett, {J. D.}",
year = "1986",
language = "English",
volume = "20",
pages = "283--287",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "4",

}

TY - JOUR

T1 - Blood pentobarbital concentrations during thiopental therapy

AU - Watson, W. A.

AU - Godley, P. J.

AU - Garriott, J. C.

AU - Bradberry, J. Chris

AU - Puckett, J. D.

PY - 1986

Y1 - 1986

N2 - The desulfuration of thiopental to pentobarbital has previously been shown to be a relatively minor pathway of thiopental metabolism. In two cases, we observed significant conversion, resulting in blood pentobarbital concentrations up to 50 percent of total blood barbiturate (thiopental and pentobarbital) concentrations. Both patients received continuous infusions of thiopental and had present a condition (hypothermia) or drug (cimetidine) known to inhibit hepatic microsomal enzyme activity. It is suggested that inhibition of hepatic microsomal enzyme activity may prevent thiopental's metabolism to its major metabolite, a carboxylic acid analogue, and increase the amount of thiopental desulfurated to pentobarbital. Inhibition of hepatic microsomal metabolism also decreases the metabolism of pentobarbital. Until further elucidation of the causes of altered thiopental metabolism is available to identify patients more likely to have elevated concentrations of pentobarbital, monitoring of blood drug concentrations in patients receiving thiopental should include determination of both thiopental and pentobarbital concentrations.

AB - The desulfuration of thiopental to pentobarbital has previously been shown to be a relatively minor pathway of thiopental metabolism. In two cases, we observed significant conversion, resulting in blood pentobarbital concentrations up to 50 percent of total blood barbiturate (thiopental and pentobarbital) concentrations. Both patients received continuous infusions of thiopental and had present a condition (hypothermia) or drug (cimetidine) known to inhibit hepatic microsomal enzyme activity. It is suggested that inhibition of hepatic microsomal enzyme activity may prevent thiopental's metabolism to its major metabolite, a carboxylic acid analogue, and increase the amount of thiopental desulfurated to pentobarbital. Inhibition of hepatic microsomal metabolism also decreases the metabolism of pentobarbital. Until further elucidation of the causes of altered thiopental metabolism is available to identify patients more likely to have elevated concentrations of pentobarbital, monitoring of blood drug concentrations in patients receiving thiopental should include determination of both thiopental and pentobarbital concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0022655428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022655428&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 283

EP - 287

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 4

ER -